Adial Pharmaceuticals- Warrants (31/07/2023) P/E Ratio

The latest P/E ratio for ADILW is -0.3. That is below the Healthcare sector average of 24.78. Investors often review this figure alongside Adial Pharmaceuticals- Warrants (31/07/2023)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, ADILW currently prints -0.3 for P/E ratio, while the sector average sits near 24.78. That is roughly 101.2% below the sector mean. Large gaps often invite a closer look at Adial Pharmaceuticals- Warrants (31/07/2023)'s growth, margins, and balance sheet.

A P/E ratio of -0.3 for Adial Pharmaceuticals- Warrants (31/07/2023) is not 'good' or 'bad' on its own. Compare it with the peer average (24.78) and with ADILW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting ADILW's P/E ratio (-0.3), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Adial Pharmaceuticals- Warrants (31/07/2023)'s P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.